Kiniksa Pharmaceuticals International (KNSA) Cash & Current Investments (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 10 years of Cash & Current Investments data on file, last reported at $525.9 million in Q2 2026.

• Quarterly Cash & Current Investments rose 24.18% year-over-year to $525.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $525.9 million (up 24.18% YoY) and the FY2025 annual result came in at $414.1 million, up 69.96% from the prior year.
• Cash & Current Investments climbed to $525.9 million in Q2 2026, from $468.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $529.3 million in Q3 2025 to a low of $138.2 million in Q2 2022.
• A 5-year average of $309.4 million and a median of $285.2 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments plunged 64.34% — and 2023, when it jumped 86.25%.
• Tracing KNSA's Cash & Current Investments over 5 years: stood at $190.6 million in 2022, then increased by 8.27% to $206.4 million in 2023, then increased by 18.05% to $243.6 million in 2024, then surged by 69.96% to $414.1 million in 2025, then grew by 27.01% to $525.9 million in 2026.
• The last three Cash & Current Investments figures came in at $525.9 million (Q2 2026), $468.1 million (Q1 2026), and $414.1 million (Q4 2025), per Business Quant data.